Oxyrane (Netherlands) a clinical-stage biopharmaceutical focused on enzyme replacement therapies for Pompe’s a lysosomal storage disease, closed a $26.5M Series D financing. Participants include Forbion Capital Partners, Morningside Group and New Science Ventures.